Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In silico evaluation, molecular docking and QSAR analysis of quinazoline-based EGFR-T790M inhibitors.

Molecular diversity - 1 Aug 2016

Asadollahi-Baboli M

Abstract excerpt

Mutated epidermal growth factor receptor (EGFR-T790M) inhibitors hold promise as new agents against cancer. Molecular docking and QSAR analysis were performed based on a series of fifty-three quinazoline derivatives to elucidate key structural and physicochemical properties affecting inhibitory activity. Molecular docking analysis identified the true conformations of ligands in the receptor's active pocket. The...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Design
Share to ErbB Receptors
Share to Molecular Docking Simulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Structure

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Quantitative Structure-Activity Relationship

Share to Quinazolines

Source

Identifiers

PMID: 27209475
DOI: 10.1007/s11030-016-9672-0

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In silico evaluation, molecular docking and QSAR analysis of quinazoline-based EGFR-T790M inhibitors.PMID 27209475Read ↗

Novel quinazoline-based EGFR kinase inhibitors: A review focussing on SAR and molecular docking studies (2015-2019).Semantic proximity Read ↗

QSAR-based models for designing quinazoline/imidazothiazoles/pyrazolopyrimidines based inhibitors against wild and mutant EGFR.Semantic proximity Read ↗

In silico target specific design of potential quinazoline-based anti-NSCLC agents.Semantic proximity Read ↗

Computational screening, ensemble docking and pharmacophore analysis of potential gefitinib analogues against epidermal growth factor receptor.Semantic proximity Read ↗

Molecular modeling, dynamic simulation, and metabolic reactivity studies of quinazoline derivatives to investigate their anti-angiogenic potential by targeting wild EGFRwt and mutant EGFRT790M receptor tyrosine kinases.Semantic proximity Read ↗

Investigating mutation-specific biological activities of small molecules using quantitative structure-activity relationship for epidermal growth factor receptor in cancer.Semantic proximity Read ↗

4D-QSAR and MIA-QSAR Studies of Aminobenzimidazole Derivatives as Fourth-generation EGFR Inhibitors.Semantic proximity Read ↗

Synthesis and in vitro biological evaluation of novel quinazoline derivatives.Semantic proximity Read ↗

Quinoxalinones as A Novel Inhibitor Scaffold for EGFR (L858R/T790M/C797S) Tyrosine Kinase: Molecular Docking, Biological Evaluations, and Computational Insights.Semantic proximity Read ↗

In silico screening of novel designed series of pyrazolidine compounds targeting Epidermal Growth Factor ReceptorSemantic proximity Read ↗

Design, synthesis and biological evaluation of EGFR kinase inhibitors that spans the orthosteric and allosteric sites.Semantic proximity Read ↗

6-Oxooxazolidine-quinazolines as noncovalent inhibitors with the potential to target mutant forms of EGFR.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.